Sissy Peterman

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven Coutré et al. · Blood · 2014 · 584 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman et al. · Blood · 2014 · 249 citations

Medicine, Oncology, Pharmacology +16

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Ian W. Flinn, Brad S. Kahl, John P. Leonard et al. · Blood · 2014 · 209 citations · Full text

Medicine, Oncology, Pharmacology +11

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, John C. Byrd, Jennifer R. Brown et al. · Blood · 2010 · 124 citations

Medicine, Oncology, Pharmacology +12

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad S. Kahl, John C. Byrd, Ian W. Flinn et al. · Blood · 2010 · 109 citations

Medicine, Oncology, Pharmacology +12